Supplement
Coluracetam is a lab-developed compound that boosts how nerve cells take up choline, the raw material for acetylcholine, a chemical messenger involved in learning and memory. In rodents with impaired cholinergic function, it preserved and increased choline uptake and improved maze learning and working memory. The evidence is very limited, though: it is mostly animal work, and company trials in Alzheimer's disease and depression with anxiety did not show benefit.
Sources: PMID 8825012; PMID 8799197; PMID 9225290
- Updated
- How we grade
- 10 studies cited
- Best evidence
- Grade D
- Conditions studied
- 3
- Outcomes
- 6
- Graded outcomes
- 0006
Evidence by condition
- Strong
- Moderate
- Limited
- Very limited
General
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| High-Affinity Choline Uptake (HACU) In rodent models with pharmacologically impaired cholinergic function (AF64A and ethylcholine aziridinium), coluracetam (MKC-231) consistently preserved and enhanced high-affinity choline uptake, increasing Vmax of HACU and Bmax of HC-3 binding approximately 1.6-1.7 fold. Effects appear specific to impaired HACU rather than enhancing normal function. | Improves (the measure goes up) | Moderate effect | 8 studies | |||
Studies that measured high-affinity choline uptake (hacu)
| ||||||
| Acetylcholine Synthesis and Release In AF64A-treated rats with reduced hippocampal acetylcholine, coluracetam significantly reversed decreases in ACh synthesis and release. The effect is mediated through enhanced choline transport rather than acetylcholinesterase inhibition, distinguishing it mechanistically from donepezil-class drugs. | Improves (the measure goes up) | Moderate effect | 2 studies | |||
Studies that measured acetylcholine synthesis and release | ||||||
| Cholinergic Neuroprotection (PCP Model) In a single rat study, subsequent exposure to coluracetam antagonized phencyclidine (PCP)-induced behavioral deficits and reduction in septal cholinergic neurons, suggesting potential neuroprotective properties for cholinergic pathways under neurotoxic stress. | Improves (the measure goes up) | Small effect | 2 studies | |||
Studies that measured cholinergic neuroprotection (pcp model) | ||||||
Alzheimer’s Disease
- Alzheimer's Disease Symptoms: improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Alzheimer's Disease Symptoms Mitsubishi Tanabe Pharma conducted a Phase 2a clinical trial for Alzheimer's disease. The trial failed to meet efficacy endpoints and development was discontinued for this indication. Despite a plausible HACU-based mechanism, human evidence does not support benefit in Alzheimer's disease. | Improves (the measure goes down) | Small effect |
Anxiety Disorders (Other)
- Depression and Anxiety Symptoms: improves
| Grade | Outcome | Effect | Size | Studies | People | Studies list |
|---|---|---|---|---|---|---|
| Depression and Anxiety Symptoms BrainCells Inc. conducted a Phase 2 clinical trial for major depressive disorder with comorbid generalized anxiety disorder. Primary endpoints were not met — no significant benefit over placebo was demonstrated. Development for this indication was discontinued. | Improves (the measure goes down) | Small effect |
Key findings
- High-Affinity Choline Uptake (HACU)Improves (the measure goes up)
- Learning and Memory (Cholinergic Deficit Models)Improves (the measure goes up)
- Acetylcholine Synthesis and ReleaseImproves (the measure goes up)
Shop Coluracetam
Third-party tested Coluracetam products. The evidence above is limited, so read it before you buy.
- Grade D
Links to Fullscript, iHerb or Thorne carry our referral, so we may earn a commission at no extra cost to you. Grades come from the research and never change based on what we earn. Fullscript asks for a free account before it shows its catalog and prices. Full disclosure
Studies cited
10 studies from PubMed
- MKC-231, a choline-uptake enhancer: (1) long-lasting cognitive improvement after repeated administration in AF64A-treated rats
- MKC-231, a choline uptake enhancer: (2) Effect on synthesis and release of acetylcholine in AF64A-treated rats
- MKC-231, a choline uptake enhancer: (3) Mode of action of MKC-231 in the enhancement of high-affinity choline uptake
- Subsequent exposure to the choline uptake enhancer MKC-231 antagonizes phencyclidine-induced behavioral deficits and reduction in septal cholinergic neurons in rats
- Effect of MKC-231 on spatial learning retention
- MKC-231, a choline uptake enhancer, activates the cholinergic nervous system
- Effects of MKC-231 on high-affinity choline uptake in the hippocampus
- Effect of the novel high affinity choline uptake enhancer 2-(2-oxopyrrolidin-1-yl)-N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)acetoamide on deficits of water maze learning in rats
- MKC-231, a choline uptake enhancer: effect on recovery from AF64A-induced learning impairment
- MKC-231, a choline uptake enhancer, ameliorates working memory deficits and decreased hippocampal acetylcholine induced by ethylcholine aziridinium ion in mice